Amneal Pharmaceuticals, Inc Class A Common Stock

Yahoo Finance • 5 days ago

Amneal Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY26 outlook

* Amneal Pharmaceuticals press release [https://seekingalpha.com/pr/20506663-amneal-reports-first-quarter-2026-financial-results] (AMRX [https://seekingalpha.com/symbol/AMRX]): Q1 Non-GAAP EPS of $0.27 beats by $0.10. * Revenue of $722... Full story

Yahoo Finance • 7 days ago

Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amneal Pharmaceuticals (NasdaqGS:AMRX) has entered a definitive agreement to acquire Kashiv BioSci... Full story

Yahoo Finance • 12 days ago

UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best drug stocks to buy according to analysts. On April 17, UBS initiated coverage of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a Buy rating and set a $19 price target. The fir... Full story

Yahoo Finance • 18 days ago

Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push

Amneal Pharmaceuticals logo Key Points Amneal will acquire Kashiv BioSciences for $750 million upfront (split 50/50 cash and equity, ~8% dilution) plus up to $350 million in milestones and royalties, expecting to close in a few months an... Full story

Yahoo Finance • 20 days ago

Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q1 2026 MANAGEMENT VIEW * "Today is a defining moment for Amneal." (Co-Founder, Co-CEO, President & Director Chirag Patel) "This morning, we announced that Amneal agrees to acquire... Full story

Yahoo Finance • 20 days ago

Stocks Supported by Iran Ceasefire Extension and Strong Earnings

The S&P 500 Index ($SPX) (SPY) today is up +0.84%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.76%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.28%.  June E-mini S&P futures (ESM26) are up +0.80%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 20 days ago

Amneal To Acquire Kashiv BioSciences; Q1 Earnings Improve; Lifts 2026 Earnings Outlook; Stock Up

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), a generic medicine and biosimilar manufacturer, announced that it has entered into a definitive agreement to acquire Kashiv BioSciences in a transaction that includes $375 million of cash an... Full story

Yahoo Finance • 20 days ago

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidanc... Full story

Yahoo Finance • 21 days ago

Amneal Announces Positive Interim Phase 4 Data For Parkinson's Drug CREXONT

(RTTNews) - Amneal Pharmaceuticals Inc. (AMRX), a biopharmaceutical company, announced on Monday positive interim data from the Phase 4 ELEVATE-PD trial for CREXONT in treating Parkinson's disease at the 2026 American Academy of Neurology... Full story

Yahoo Finance • 23 days ago

Amneal rated Buy in new research coverage at UBS as growth pipeline expands

[Anatomical 3D illustration of the transparent human head interior.] AntonioGuillem/iStock via Getty Images UBS on Friday initiated coverage of Amneal Pharmaceuticals (AMRX [https://seekingalpha.com/symbol/AMRX]) with a Buy rating and a $... Full story

Yahoo Finance • 29 days ago

2 Cash-Producing Stocks to Research Further and 1 We Brush Off

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not all companies are created equal, and StockStory is here to surface the ones with... Full story

Yahoo Finance • last month

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

Amneal Pharmaceuticals LLC Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or... Full story

Yahoo Finance • last month

Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month

Amneal Pharmaceuticals LLC BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assistance foundati... Full story

Yahoo Finance • last month

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 2 months ago

3 Reasons to Avoid AMRX and 1 Stock to Buy Instead

Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may have investors wondering how to approach the situation. Is now the time to buy Amnea... Full story

Yahoo Finance • 2 months ago

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q42025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q42025 Adjusted Net... Full story

Yahoo Finance • 3 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds.Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility The next stock on our... Full story

Yahoo Finance • 5 months ago

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasd... Full story

Yahoo Finance • 5 months ago

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each dose... Full story

Yahoo Finance • 5 months ago

Amneal to Participate in Upcoming Investor Conferences

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in follo... Full story